U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H32F3N3O4
Molecular Weight 495.5345
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILODOSIN

SMILES

C[C@H](CC1=CC(C(N)=O)=C2N(CCCO)CCC2=C1)NCCOC3=CC=CC=C3OCC(F)(F)F

InChI

InChIKey=PNCPYILNMDWPEY-QGZVFWFLSA-N
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1

HIDE SMILES / InChI
Molecular Formula C25H32F3N3O4
Molecular Weight 495.5345
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical. The drug was approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia.

Originator

Approval Year

2008
174
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 0.32 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
RAPAFLO

Approved Use

RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
61.6 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SILODOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
373.4 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SILODOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SILODOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022206s012lbl.pdf
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SILODOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
48 mg 1 times / day multiple, oral
Highest studied dose
Dose: 48 mg, 1 times / day
Route: oral
Route: multiple
Dose: 48 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21114397
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54
healthy, 19 - 45
n = 6
Health Status: healthy
Age Group: 19 - 45
Sex: M
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/21114397
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54
DLT: Postural hypotension...
Dose limiting toxicities:
Postural hypotension
Sources:
https://pubmed.ncbi.nlm.nih.gov/21114397
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54
12 mg single, oral
Highest studied dose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
healthy, 23 ± 1.4
n = 8
Health Status: healthy
Age Group: 23 ± 1.4
Sex: M
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
Other AEs: Nervous system disorder NOS, Fatigue...
Other AEs:
Nervous system disorder NOS (13%)
Fatigue (13%)
Dizziness (13%)
Hematuria (13%)
Leukocyturia (13%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf
Page: p.6
unhealthy
n = 466
Health Status: unhealthy
Condition: Benign prostatic hyperplasia
Sex: M
Population Size: 466
Sources:
https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf
Page: p.6
Disc. AE: Retrograde ejaculation...
AEs leading to
discontinuation/dose reduction:
Retrograde ejaculation (2.8%)
Sources:
https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf
Page: p.6
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Benign prostatic hyperplasia
Sex: M
Sources:
https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf
Page: p.3
Other AEs: Intraoperative floppy iris syndrome...
Other AEs:
Intraoperative floppy iris syndrome
Sources:
https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf
Page: p.3
AEs

AEs

AESignificanceDosePopulation
Postural hypotension DLT
48 mg 1 times / day multiple, oral
Highest studied dose
Dose: 48 mg, 1 times / day
Route: oral
Route: multiple
Dose: 48 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21114397
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54
healthy, 19 - 45
n = 6
Health Status: healthy
Age Group: 19 - 45
Sex: M
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/21114397
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54
Dizziness 13%
12 mg single, oral
Highest studied dose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
healthy, 23 ± 1.4
n = 8
Health Status: healthy
Age Group: 23 ± 1.4
Sex: M
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
Fatigue 13%
12 mg single, oral
Highest studied dose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
healthy, 23 ± 1.4
n = 8
Health Status: healthy
Age Group: 23 ± 1.4
Sex: M
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
Hematuria 13%
12 mg single, oral
Highest studied dose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
healthy, 23 ± 1.4
n = 8
Health Status: healthy
Age Group: 23 ± 1.4
Sex: M
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
Leukocyturia 13%
12 mg single, oral
Highest studied dose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
healthy, 23 ± 1.4
n = 8
Health Status: healthy
Age Group: 23 ± 1.4
Sex: M
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
Nervous system disorder NOS 13%
12 mg single, oral
Highest studied dose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
healthy, 23 ± 1.4
n = 8
Health Status: healthy
Age Group: 23 ± 1.4
Sex: M
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/21804212
Page: p.1242
Retrograde ejaculation 2.8%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf
Page: p.6
unhealthy
n = 466
Health Status: unhealthy
Condition: Benign prostatic hyperplasia
Sex: M
Population Size: 466
Sources:
https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf
Page: p.6
Intraoperative floppy iris syndrome
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf
Page: p.3
unhealthy
Health Status: unhealthy
Condition: Benign prostatic hyperplasia
Sex: M
Sources:
https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf
Page: p.3
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587

inducer
781
inhibitor
1767

inducer
389

substrate
1037
inhibitor
1852

substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2C19
1478

CYP2E1
882
UGT2B7
389

P-gp
1537

CYP1A1
349

CYP1A2
1054

CYP2A6
543

CYP2C19
991

CYP2E1
667

UGT1A1
418

UGT1A3
422

UGT1A6
307

UGT1A9
380

UGT1A10
291

UGT2B15
203
CYP1A2
701

CYP2C8
168

CYP2C19
293

P-gp
257
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2A6
739
 no
CYP2C19
1553
 no
CYP2C19
1553
 no
CYP2C8
965
 no
CYP2C9
1819
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A4
1925
 no
CYP3A4
1925
 no
P-gp
1650
 no
no (co-administration study)
Comment: silodosin did not significantly affect the PK of digoxin
Page: 5.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT1A1
418
 no
UGT1A10
291
 no
UGT1A3
422
 no
UGT1A6
307
 no
UGT1A9
380
 no
UGT2B15
203
 no
CYP1A1
349
 no
no (co-administration study)
Comment: furafylline did not affect silodosin metabolism
Page: 16.0
CYP1A2
1054
 no
no (co-administration study)
Comment: furafylline did not affect silodosin metabolism
Page: 16.0
CYP2A6
543
 no
no (co-administration study)
Comment: coumarin did not affect silodosin metabolism
Page: 16.0
CYP2C19
991
 no
no (co-administration study)
Comment: S-mephenytoin did not affect silodosin metabolism
Page: 16.0
CYP2C9
1037
 no
no (co-administration study)
Comment: sulfafenazole did not affect silodosin metabolism
Page: 16.0
CYP2D6
1217
 no
no (co-administration study)
Comment: quinidine did not affect silodosin metabolism
Page: 16.0
CYP2E1
667
 no
no (co-administration study)
Comment: diethyldithiocarbamate did not affect silodosin metabolism
Page: 16.0
UGT2B7
389
 yes
CYP3A4
1737
 yes
yes (co-administration study)
Comment: ketaconzaole increased sildosin Cmax by 3.8-fold and AUC by 3.2-fold
Page: 5, 11, 12
P-gp
1537
 yes
yes (co-administration study)
Comment: ketaconzaole increased sildosin Cmax by 3.8-fold and AUC by 3.2-fold
Page: 17.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA001VHU
https://www.aablocks.com/goods/Goods/detail?id=AA001VHU
AK Scientific, Inc. (AKSCI)
66700
http://www.aksci.com/item_detail.php?cat=66700
Aaron Chemicals
AR001W9M
http://www.aaronchem.com/160970-54-7
AbMole Bioscience
M3551
http://www.abmole.com/products/silodosin.html
Achemo Scientific Limited
AC-63538
http://www.achemo.com/search/?Keyword= 160970-54-7
Achemtek
0101-002081
http://www.achemtek.com/160970-54-7
Acorn PharmaTech
ACN-S002529
http://www.acornpharmatech.com/
Active Biopharma
ABP000202
http://www.activebiopharma.com/160970-54-7
Alfa Chemistry
AP160970547
https://reagents.alfa-chemistry.com/product/silodosin-cas-160970-54-7-5943.html
Alfa Chemistry
1051374-52-7
https://www.alfa-chemistry.com/cas_1051374-52-7.htm
Allbio Pharm Co., Ltd
AF15549
http://www.allbiopharm.com/product/n/AF15549
Alsachim
1524
http://www.alsachim.com/product-C2122-glo.bal-view.html
Ambeed
A632990
https://www.ambeed.com/products/160970-54-7.html
Angel Pharmatech
AG-19708
http://www.angelpharmatech.com/160970-54-7.html
ApexBio Technology
A8521
http://www.apexbt.com/silodosin.html
Aurora Fine Chemicals LLC
A24.077.565
http://online.aurorafinechemicals.com/info?ID=A24.077.565
Aurum Pharmatech LLC
W-5225
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5225
AvaChem Scientific
2658
http://www.avachem.com/productSearch.asp?2658
Axon MedChem
3112
https://www.axonmedchem.com/product/3112
BLD Pharm
BD161491
http://www.bldpharm.com/products/160970-54-7.html
BioChemPartner
BCP02143
http://www.biochempartner.com/160970-54-7-BCP02143
BioSynth
Q-102517
https://www.biosynth.com/en/products/chemical-intermediates/advanced-intermediates/products/Q-102517.html
CSNpharm
CSN12335
https://www.csnpharm.com/products/silodosin.html
Chem Scene
CS-0284
http://www.chemscene.com/160970-54-7.html
ChemFaces
CFN90002
http://www.chemfaces.com/natural/Silodosin-CFN90002.html
ChemMol
30116026
http://www.chemmol.com/chemmol/30116026.html
ChemMol
49401385
http://www.chemmol.com/chemmol/49401385.html
Chemspace
CSSB00016998219
https://chem-space.com/CSSB00016998219
Clearsynth
CS-O-11743
https://www.clearsynth.com/en/CSO11743.html
DC Chemicals
DCAPI1485
http://www.dcchemicals.com/product_show-Silodosin.html
Hairui
HR117388
http://www.hairuichem.com/en/product/160970-54-7.html
Lab Network
LN01296344
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01296344
MedChem Express
HY-10122
https://www.medchemexpress.com/Silodosin.html
OChem
24781
http://www.ocheminc.com/index.php?act=psearch&pid=970S649
Renno Tech
RL02066
http://www.rennotech.com/product_show.asp?id=2315
Selleck Chemicals
S1613
http://www.selleckchem.com/products/Silodosin(Rapaflo).html
Sigma-Aldrich
SML2142_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/sml2142?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S543190
http://www.smolecule.com/products/s543190
Synblock Inc
SB19320
http://www.synblock.com/product/160970-54-7.html
THE BioTek
bt-283302
https://www.thebiotek.com/product/inhibitors/bt-283302
Tocris
6663
https://www.tocris.com/products/silodosin_6663
TripleBond
CS0060
http://www.triplebond-canada.com/prod/1593/
VladaChem
VL281883-10MG
https://www.vladachem.com/product.php?products=160970-54-7
abcr GmbH
AB479551
http://www.abcr.com/shop/en/AB479551
iChemical
EBD33557
http://www.ichemical.com/products/160970-54-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Cardiovascular effects of the selective alphalA-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction.
2006
[Pharmacological and clinical profile of silodosin (URIEF Cap. 2 mg, 4 mg)].
2006 Oct
Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia.
2007 Dec
Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding.
2007 Jan
Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia.
2007 Jul
Different affinities of native alpha1B-adrenoceptors for ketanserin between intact tissue segments and membrane preparations.
2008 Apr 28
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.
2009 Fall
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
2009 Jun
New drugs: milnacipran hydrochloride, fesoterodine fumarate, and silodosin.
2009 Mar-Apr
Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
2010 Apr
Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
2010 Dec
Gateways to clinical trials.
2010 Nov
Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity.
2010 Oct
Silodosin in the treatment of benign prostatic hyperplasia.
2010 Oct 27
Patents

Patents

20030133978
1
20040132697
1
20040132728
1
20050065124
2
20050101607
4
JP2009067737A
1

Sample Use Guides

In Vivo Use Guide
The recommended dose is 8 mg orally once daily with a meal. The dose can be reduced to 4 mg for those with moderate renal impairment.
Route of Administration: Oral
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/23226423
Human prostate tissue were treated with silodosin at 3 uM added 15 min before application of noradrenaline (30 uM) to study the inhibition of noradrenaline-activated Transcription Factors Elk1 and SRF.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:49:12 GMT 2023
Edited
by admin
on Fri Dec 15 15:49:12 GMT 2023
Record UNII
CUZ39LUY82
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SILODOSIN
DASH   EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
RAPAFLO
Brand Name English
SILODOSIN [ORANGE BOOK]
Common Name English
KSO-0400
Common Name English
URIEF
Brand Name English
SILODOSIN [EMA EPAR]
Common Name English
(-)-1-(3-HYDROXYPROPYL)-5-((2R)-2-((2-(2-(2,2,2-TRIFLUOROETHOXY)PHENOXY)ETHYL)AMINO)PROPYL)-2,3-DIHYDRO-1H-INDOLE-7-CARBOXAMIDE
Systematic Name English
2,3-DIHYDRO-1-(3-HYDROXYPROPYL)-5-((2R)-2-((2-(2-(2,2,2-TRIFLUOROETHOXY)PHENOXY)ETHYL)AMINO)PROPYL)-1H-INDOLE-7-CARBOXAMIDE
Systematic Name English
KAD-3213
Code English
SILODOSIN [JAN]
Common Name English
silodosin [INN]
Common Name English
SILODOSIN [MI]
Common Name English
SILODYX
Brand Name English
RAPILIF
Brand Name English
SILODOSIN [VANDF]
Common Name English
Silodosin [WHO-DD]
Common Name English
KMD-3213
Code English
SILODAL
Brand Name English
SILODOSIN [MART.]
Common Name English
UROREC
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS UROREC (AUTHORIZED: PROSTATIC HYPERPLASIA)
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
NDF-RT N0000175553
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
WHO-ATC G04CA04
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
LIVERTOX NBK548170
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
NDF-RT N0000000099
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
EMA ASSESSMENT REPORTS SILODYX (AUTHORIZED: PROSTATIC HYPERPLASIA)
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
WHO-VATC QG04CA04
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
Code System Code Type Description
SMS_ID
100000090781
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID40167045
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
DRUG CENTRAL
4151
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
INN
8043
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
DRUG BANK
DB06207
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
CAS
160970-54-7
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
DAILYMED
CUZ39LUY82
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
RXCUI
720825
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m9912
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
SILODOSIN
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
NCI_THESAURUS
C81372
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
EVMPD
SUB23152
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
FDA UNII
CUZ39LUY82
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL24778
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
IUPHAR
493
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
PUBCHEM
5312125
Created by admin on Fri Dec 15 15:49:12 GMT 2023 , Edited by admin on Fri Dec 15 15:49:12 GMT 2023
PRIMARY
Related Record Type Details
ALPHA-1A ADRENERGIC RECEPTOR
TARGET -> INHIBITOR
Selectivity of silodosin determined in cloned human α1-adrenergic receptor (α1-AR) subtypes in cultured Chinese hamster ovary cells.Silodosin has greater affinity for the α1A-adrenergic receptor than for the α1B-adrenergic receptor (by a factor of 583), minimizing the propensity for blood pressure-related adverse effects mediated by α1B blockade.
Ki
Structure of SILODOSIN
CUMULATIVE EXCRETION
URINE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
ALPHA-1B ADRENERGIC RECEPTOR
OFF-TARGET->INHIBITOR
Selectivity of silodosin determined in cloned human α1-adrenergic receptor (α1-AR) subtypes in cultured Chinese hamster ovary cells.
Ki
Structure of SILODOSIN
CUMULATIVE EXCRETION
FECAL
ALPHA-1D ADRENERGIC RECEPTOR
OFF-TARGET->INHIBITOR
Related Record Type Details
Structure of KDM-3289
METABOLITE -> PARENT
MINOR
FECAL; PLASMA; URINE
Structure of KDM-3295
METABOLITE -> PARENT
MEDIATOR-S9+NAD
MINOR
FECAL; PLASMA; URINE
Structure of KMD-3213G
METABOLITE LESS ACTIVE -> PARENT
Major in plasma
MAJOR
PLASMA; URINE
Structure of KMD-3241G
METABOLITE ACTIVE -> PRODRUG
Mediator: UDP-glucuronosyltransferase
MAJOR
PLASMA; URINE
Structure of KMD-3293
METABOLITE LESS ACTIVE -> PARENT
Major in plasma and urine; S9+NAD mediator; Does not significanly contribute to the efficacy
MAJOR
FECAL; PLASMA; URINE
Structure of KMD-3241
METABOLITE -> PARENT
MINOR
FECAL; PLASMA; URINE
Related Record Type Details
Structure of SILODOSIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966